Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
General qualifying criteria include: Adults with a BMI of 30 or higher (clinical obesity), or BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol Adults who have not achieved adequate weight loss through diet and lifestyle changes alone Patients without a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 Patients who are not pregnant or planning pregnancy Patients without a history of pancreatitis (assessed case by case) At your consultation, Tiffany reviews your health history, discusses your weight loss goals and previous experiences, and determines whether GLP-1 therapy is appropriate for you and which medication and dosing approach makes the most sense
Weight-loss medication has moved fast over the past few years, and semaglutidethe active ingredient in Ozempic and Wegovyhas been at the center of that shift
eating right away means your stomach receives a dual assault of food volume and heightened GLP-1 signaling
Elsevier (2013)
The next most common side effect, diarrhea, occurs in 30% of people on Wegovy (compared to 16% of people on a placebo)
Formulation strategy under appetite suppression One of the more challenging implications for manufacturers is that traditional reformulation levers such as reducing sugar or fat while maintaining portion size may be insufficient in a GLP-1-influenced environment
